Xocova is a drug owned by Shionogi Inc. It is protected by 3 US drug patents filed in 2026 out of which none have expired yet. Xocova's patents will be open to challenges from 29 May, 2030. Based on its patents and exclusivities, its generic launch date is estimated to be May 01, 2042. Details of Xocova's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| US12559474 | Triazine Derivatives Having Virus Replication Inhibitory Activity And Pharmaceutical Composition Comprising The Same |
May, 2042
(15 years from now) | Active |
| US11814368 | Triazine Derivatives Having Virus Replication Inhibitory Activity And Pharmaceutical Composition Comprising The Same |
May, 2042
(15 years from now) | Active |
| US9150546 | Triazine Derivative And Pharmaceutical Composition Comprising The Same |
Dec, 2030
(4 years from now) | Active |
FDA has granted several exclusivities to Xocova. Till the time
these exclusivities
are active, no other company can market a generic or bioequivalent version of Xocova, regardless of the status of it's patents. These exclusivities hence play a crucial role in
delaying the generic
launch. Given below are details of the exclusivities granted to
Xocova.
Exclusivity Information
Xocova holds 1 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2031. Details of Xocova's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 29, 2031 |
US patents provide insights into the exclusivity only within the United States, but
Xocova is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Xocova's family patents as well as insights into
ongoing legal events
on those patents.
Xocova's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Xocova's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be May 01, 2042 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Xocova Generics:
There are no approved generic versions for Xocova as of now.
About Xocova
Xocova is a drug owned by Shionogi Inc. Xocova uses Ensitrelvir as an active ingredient. Xocova was launched by Shionogi in 2026.
Approval Date:
Xocova was approved by FDA for market use on 29 May, 2026.
NCE-1 date:
NCE-1 date also known as the four year date occurs four years after the original drug approval and marks the first opportunity for a generic manufacturer to file an ANDA with a Paragraph IV certification. This is the earliest point when generic competition might begin, provided the challenge is successful. Since the approval date for Xocova is 29 May, 2026, its NCE-1 date is estimated to be 29 May, 2030.
Active Ingredient:
Xocova uses Ensitrelvir as the active ingredient. Check out other Drugs and Companies using Ensitrelvir ingredient
Dosage:
Xocova is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 125MG | TABLET | Prescription | ORAL |